BIOLASE (BIOL) Stock Price, News & Analysis

Company Overview

BIOLASE, Inc. (NASDAQ: BIOL) is a medical device company specializing in the design, development and manufacture of laser systems for dentistry. The company’s laser platforms enable minimally invasive dental procedures, combining laser energy with water spray to perform both hard‐tissue and soft‐tissue applications. By integrating advanced laser technology into routine dental care, BIOLASE aims to improve patient comfort, reduce the need for anesthesia and shorten procedure times.

The company’s flagship products include the Waterlase® family of erbium lasers and the Epic™ series of diode lasers. Waterlase systems are indicated for a wide range of applications, including cavity preparation, bone surgery, endodontics, periodontal therapy and oral surgery. Epic diode lasers are used primarily for soft‐tissue procedures such as gum recontouring, pain management and bacterial reduction. BIOLASE also offers a comprehensive portfolio of handpieces, tips and accessories to support clinical workflows and practice growth.

Founded in 1984 and headquartered in Irvine, California, BIOLASE has established a global distribution network that spans North America, Europe, Asia and other international markets. The company works with dental equipment dealers, group purchasing organizations and strategic partners to expand market reach and provide training and support to dental professionals. BIOLASE’s research and development efforts are focused on enhancing laser performance, broadening procedural indications and integrating digital dentistry solutions.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: $0.0002 to $0.0125
• 52-Week Range: $0.02 to $1.94
• Volume: 5 shs
• Average Volume: 2.58 million shs
• Market Capitalization: $6.68 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIOL Stock Analysis - Frequently Asked Questions

How have BIOL shares performed this year?

BIOLASE's stock was trading at $0.0120 on January 1st, 2025. Since then, BIOL shares have decreased by 98.3% and is now trading at $0.0002.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share for the quarter, topping analysts' consensus estimates of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative trailing twelve-month return on equity of 1,782.73% and a negative net margin of 41.65%.

When did BIOLASE's stock split?

BIOLASE shares reverse split on Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 10/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Dental equipment & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BIOL
• Previous Symbol: NASDAQ:BLTI
• CIK: 811240
• Web: www.biolase.com
• Phone: (949) 361-1200
• Fax: 949-273-6677
• Employees: 160
• Year Founded: 1987

Profitability

• EPS (Trailing Twelve Months): ($14.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.63 million
• Net Margins: -41.65%
• Pretax Margin: -41.56%
• Return on Equity: -1,782.73%
• Return on Assets: -55.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $48.83 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 33,407,000
• Free Float: 33,317,000
• Market Cap: $6.68 thousand
• Optionable: Not Optionable
• Beta: 0.67